High-risk lesions in immunosuppression

Role and principles

Recognise accelerated keratinocyte and virus-associated cancer risk during immune suppression, lower thresholds for urgent biopsy, coordinate surveillance and prevention, and modify systemic treatment only through multidisciplinary care.

Immune surveillance restrains ultraviolet- and virus-altered cells. When it is suppressed, SCC becomes more frequent and aggressive, while BCC, melanoma, Merkel-cell carcinoma, Kaposi sarcoma and HPV-associated anogenital or periungual cancers also increase. Record the immune diagnosis, medicines, transplant type and date, rejection history, previous cancers and cumulative field treatments.

Surveillance must be systematic and accessible. Examine areas patients cannot see and teach monthly self-checking with a partner or mirror when acceptable. In richly pigmented skin, focus beyond erythema: new keratin, tenderness, ulceration, scar change and nodal findings are important. Immunosuppression removes any justification for assuming a non-sun-exposed or pigmented lesion is low risk.

Prevention is layered. Use ultraviolet protection, smoking cessation support, HPV prevention where eligible, field therapy and prompt tumour treatment. High-burden transplant recipients may receive specialist systemic chemoprevention such as acitretin, but mucocutaneous, lipid, hepatic and teratogenic toxicity requires expert selection and monitoring. Changing the immunosuppressive regimen can reduce cancer risk but may endanger the graft or underlying disease.

Key points

Solid-organ transplant recipients have a markedly increased cutaneous SCC burden, with greater multiplicity, recurrence, nodal spread and disease-specific mortality.
Chronic lymphocytic leukaemia, lymphoma, HIV, stem-cell transplantation and long-term immunosuppressive medicines also change tumour behaviour and diagnostic thresholds.
Do not wait for a lesion to satisfy every standard size criterion; rapid growth, pain, keratin, ulceration or an outlier pattern warrants urgent biopsy.
Examine the whole skin, scalp, lips, ears, palms, soles, nails and genital region according to consent and risk, plus relevant nodal basins.
Provide regular specialist surveillance based on immune state and previous tumour burden, with rapid access between routine appointments.
Combine shade, clothing, broad-brimmed hats and broad-spectrum sunscreen; sunscreen complements rather than replaces physical protection.
Treat actinic field change and every suspicious invasive focus separately; field cream must not conceal a thick or tender SCC.
Never stop or reduce transplant, cancer or inflammatory-disease immunosuppression independently; balance graft or disease control with cancer risk in the multidisciplinary team.

Assessment and patient selection

Explosive keratinocyte burden

Numerous new actinic keratoses, horns or SCCs over months signals inadequate immune control and high field risk.

Aggressive SCC phenotypeRed flag

Rapidly enlarging painful indurated keratin, ulceration, lip or ear site and recurrence demand urgent assessment.

Perineural or nodal diseaseRed flag

Numbness, weakness, severe pain or a firm regional node indicates possible advanced SCC.

Virus-associated lesions

Extensive warts, anogenital plaques, violaceous Kaposi-like lesions or umbilicated papules require broader immune and oncological differential diagnosis.

Field-treatment outlier

One tender thick lesion among many rough keratoses needs biopsy before the surrounding field is treated.

Red flags requiring action

Any rapidly growing, painful, indurated, ulcerated or bleeding lesion, lip or ear tumour, neurological symptom, regional node, widespread eruptive lesions or a changing transplant-associated scar requires urgent skin-cancer assessment.

Baseline assessment

01
Baseline full-skin and node examinationFirst step
Why
Establish tumour burden, field damage and sites needing biopsy or surveillance.
Interpretation and limitations
Document a lesion map and immune context; examination interval depends on new and previous tumour frequency.
02
Early adequate-depth biopsy
Why
Diagnose a suspicious lesion before rapid progression or field treatment obscures it.
Interpretation and limitations
Sample the most indurated or ulcerated area and provide immune status and prior cancer history to pathology.
03
Histological high-risk review
Why
Identify depth, differentiation, nerves, vessels, margins and aggressive subtype.
Interpretation and limitations
Immune suppression adds risk even when other features appear moderate and should be visible to the multidisciplinary team.
04
Nodal ultrasound and imaging
Why
Assess clinical nodes, perineural symptoms or deeply invasive tumours.
Interpretation and limitations
Use image-guided sampling for suspicious nodes and anatomy-directed MRI or CT for spread.
05
Chemoprevention safety tests
Why
Establish liver, lipid, pregnancy and medicine baseline before specialist acitretin.

Interventions

01Routine high-risk surveillanceBuild a rapid-access prevention systemFirst stepA patient has ongoing immune suppression with no current invasive warning.

1Record immune therapy and previous tumours, perform risk-based full-skin and node examination and set the next interval.
2Teach practical self-examination and layered ultraviolet protection and provide direct instructions for lesions that cannot wait.
3Treat field change and review HPV prevention, smoking and occupational exposure while keeping invasive outliers outside field protocols.

02New suspicious lesionLower the biopsy thresholdA lesion grows, hurts, keratinises, ulcerates, bleeds or differs from the surrounding field.

1Document speed, site, dimensions, nodes, neurological symptoms and the precise immune regimen.
2Arrange urgent specialist biopsy with adequate depth and avoid destructive empirical treatment.

Medicines and treatment safety

Reduces new keratinocyte cancers in selected very high-burden transplant recipients while treatment continues.

Acitretin capsules

Use only a specialist-selected individual dose for secondary chemoprevention, commonly starting low and titrating to tolerability under the current SmPC.

Highly teratogenic with prolonged post-treatment pregnancy prevention, hepatotoxic and lipid-altering; review alcohol, interactions, mood, bone and mucocutaneous effects and never use without expert monitoring.

Targets, monitoring and follow-up

Record the number, site and pathology of new cancers per year to assess trajectory and chemoprevention value.
At each review inspect scars, field change, nodes and areas the patient cannot readily examine.
For acitretin, monitor liver tests, lipids, pregnancy prevention where applicable and mucocutaneous and musculoskeletal toxicity.
Confirm that transplant or disease specialists own any immunosuppression modification and that graft or disease markers remain safe.
Audit urgent access from patient-reported warning lesion to examination and biopsy, not only attendance at routine surveillance.

Special situations

Immunity changes biology

The same-appearing SCC can recur and metastasise more readily in an immune-suppressed host.

Field therapy is not triage

A broad fluorouracil course cannot substitute for biopsy of one thick, tender or rapidly changing outlier.

Tumour rate is measurable

Cancers per patient-year provides a practical baseline for evaluating systemic prevention.

The graft remains central

Cancer-risk reduction must be balanced against rejection and organ loss through shared specialist decisions.

Common pitfalls

01
Using standard low-risk follow-up intervals despite several SCCs arising each year.
02
Treating a thick painful lesion as field change without biopsy.
03
Reducing transplant immunosuppression independently and precipitating rejection.
04
Prescribing acitretin without the extended teratogenic, liver and lipid safeguards.
05
Limiting examination to sun-exposed skin and missing genital, acral or scar-associated cancer.